Pharmacokinetics of levofloxacin in healthy Thai male volunteers

Journal of the Medical Association of Thailand

Volumn 82, Issue 11, 1999, Pages 1126-1134

  Chulavatnatol, Suvatna ^a   Vibhagool, Asda ^b   Sriapha, Charuwan ^b   Chindavijak, Busba ^a   Wananukul, Winai ^b   Sirisangtragul, Chuleekorn ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Fluoroquinolone; Levofloxacin; Pharmacokinetics

Indexed keywords

LEVOFLOXACIN;

ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; HUMAN; HUMAN EXPERIMENT; MALE; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; THAILAND; VOLUNTEER;

ANTI-INFECTIVE AGENTS; CROSS-OVER STUDIES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; OFLOXACIN;

EID: 0041730423     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Eliopoulos GM, Wennersten CB, Moellering RC Jr. Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. Diagn Microbiol Infect Dis 1996;25:35-41.
2. Hammerschlag MR, Wumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, levofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992;36:1573-4.
3. Baltch AL, Smith RP, Ritz W. Inhibitory and bactericidal activities of levofloxacin, ofloxacin, erythromycin and rifampin used singly and in combination against Legionella pneumophila. Antimicrob Agents Chemother 1995;39:1661-6.
4. Langtry HD, Lamb HM. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 1998;56:487-515.
5. Basci NE, Hanioglu-Kargi S, Soysal H, et al. Determination of ofloxacin in human aqueous humour by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 1997;15:663-6.
6. Wonnacott RJ, Wonnacott TH. (eds) Econometrics. New York: Wiley, 1970:132.
7. Rowland M, Tozer TN. Clinical pharmacokinetics: Concepts and applications. 3rd ed. Philadelphia: Williams & Wilkins, 1995.
8. Shargel L, Yu ABC. Applied biopharmaceutics and pharmacokinetics. 3rd ed. Connecticut: Appleton & Lange, 1993.
9. Goodwin SD, Gallis HA, Chow AT, et al. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1994;38:799-804.
10. Child J, Mortiboy D, Andrews JM, et al. Open-label crossover study to determine the pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother 1995;39:2749-51.
11. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279: 125-9.
12. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
13. Chien SC, Chow AT, Rogge MC, et al. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine. Antimicrob Agents Chemother 1997;41:1765-9.
14. Chien SC, Chow AT, Natarajan J, et al. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997;41:1562-5.
15. Chien SC, Rogge MC, Gisclon LG, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 1997;41:2256-60.
16. Lee LJ, Hafkin B, Lee ID, et al. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997;41:2196-220.
17. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32: 101-19.
18. Wagner JG. Dosage intervals based on mean residence times. J Pharm Sci 1987;76:35-8.
19. Dudley MN, Blaser J, Gilbert D, et al. Bactericidal activity of ciprofloxacin against Ps. aeruginosa and other bacteria in an in vitro capillary model. Rev Infect Dis 1988;10:s34-5.
20. Peloquin CA, Cumbo TJ, Nix DE, et al. Intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentrations, organism MIC, and clinical condition on bacterial eradication. Arch Intern Med 1989;149:2269-73.
21. Aswapokee N. New quinolone for respiratory tract infection. 29th World Conference of IUAPLD/ UICTMR Global Congress on Lung; 1998 Nov 23-26: Bangkok, Thailand.